Press Releases American BriVision (Holding) Corporation OTC Markets

Equities

ABVC

US0247332069

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals	07-02	AQ
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K	05-24	PU
Promising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M - Form 8-K	05-15	PU
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	05-09	AQ
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K	05-09	PU
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share	04-18	AQ
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	04-17	AQ
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M	04-10	AQ
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M	03-26	AQ
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars	03-21	AQ
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine	03-19	AQ
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update	03-14	AQ
ABVC BioPharma : Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - Form 8-K	03-14	PU
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues	02-15	AQ
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)	02-12	AQ
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share	02-08	AQ
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	01-08	AQ
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees	01-03	AQ
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials	12-05	AQ
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M	11-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases American BriVision (Holding) Corporation OTC Markets

Equities

ABVC

US0247332069

Press Releases

Filters